Results Disproportionate reporting of GI [i.e., nausea (ROR 4.01, 95% CI 3.854.19)] and pancreato-biliary disorders [i.e., pancreatitis (ROR 3.63, 95% CI 3.154.19)], diabetic retinopathy (ROR 4.14, 95% CI 2.347.30), and medullary thyroid cancer (ROR 13.67, 95% CI 4.3542.96) was detected
Reports describe darkened pigmentation in targeted dermal tissues without the need for ultraviolet exposure, highlighting its potential use in controlled photoprotection and pigmentation studies
If you do change your injection time, maintain consistency thereafter and follow your healthcare provider's guidance
Practical considerations and rationale for glucagon-like peptide-1 receptor agonist plus sodium-dependent glucose cotransporter-2 inhibitor combination therapy in type 2 diabetes
Svedberg and Hedenius, 1933)